



Advances in Immunology for Ocular Surface Diseases and Vitreoretinal Pathologies

Guest Editor:

Dr. Kofi Asiedu

College of Optometry, University
of Houston, Houston, TX, USA

Deadline for manuscript
submissions:

31 July 2025

Message from the Guest Editor

Dear Colleagues,

Recent studies have advanced ocular immunology, particularly in the context of diabetes, ocular allergies, uveitis, retinal disease, and dry eye disease. Despite these developments, there are still many unanswered questions in this growing field, highlighting the need for further research. This upcoming Issue will focus on the mechanisms and treatment of corneal neuroimmune abnormalities, specifically in metabolic diseases such as type 1 diabetes, diabetic chronic kidney disease, type 2 diabetes, metabolic syndrome, and prediabetes.

This Issue will examine how both diabetic and non-diabetic medications affect corneal neuroimmune features in conditions of impaired glycemia. Key areas of emphasis will include ocular allergies, dry eye disease, uveitis, and ischaemic retinopathy.

Additionally, the Issue will welcome original research papers and reviews concerning ocular surface inflammation and retinal inflammation in diabetes, age-related macular degeneration, and related complications





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)